Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

any-sponsored, randomized, placebo-controlled Phase 2 trial of apatorsen in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. Approximately 180 patients have been randomized into Borealis-1 at 55 clinical sites throughout North America and Europe. The primary endpoint of the trial is overall survival and data are expected to be available in the the second-half of 2014.
  • In August 2013, the Company announced initiation of patient enrollment in the Spruce™ clinical trial. Spruce is an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 trial evaluating apatorsen in patients with previously untreated advanced non-squamous NSCLC.
  • In addition to Borealis-1 and Spruce, as part of the ORCA™ (Ongoing Studies Evaluating Treatment Resistance in CAncer) program, apatorsen is currently being evaluated in the following investigator-sponsored, randomized Phase 2 trials across four tumor types. Recent updates to additional ORCA trials are as follows:
  • The Borealis-2™ Trial was initiated in April 2013 and is currently enrolling patients. This investigator-sponsored, randomized, open-label Phase 2 trial is evaluating apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy. Borealis-2 aims to enroll approximately 200 patients.
  • The Cedar™ Trial is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Plans to initiate Cedar were announced in May 2013. The trial aims to enroll approximately 140 patients and is being conducted in the UK.
  • The Rainier™ Trial is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination wi
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... 2015 Precyse, a leader in health information ... as part of its long term growth plan, the ... by investment firm Pamplona Capital Management (Pamplona).  Precyse,s board ... Partners and NewSpring Capital, have approved this corporate transaction. ... 5,000 healthcare facilities and systems across the ...
    (Date:7/1/2015)... Research and Markets( ... "2015 Strategies in the Home/Self Testing Market" ... new 175-page report provides analysis of the major ... meters), pregnancy, ovulation, and occult blood. The report ... and competitive profiles. The growing economic ...
    (Date:7/1/2015)... 2015 Dynatronics Corporation (the "Company") (NASDAQ: ... rehabilitation and physical therapy products, announced today that ... led by affiliates of Prettybrook Partners LLC (collectively, ... the healthcare industry. The financing provides Dynatronics with ... potential strategic acquisitions.  "We enthusiastically ...
    Breaking Medicine Technology:Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
    ... YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a ... catalogue: Hormone Replacement Therapy in ... 2017 http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... Assessment and Market Forecasts to 2017 ...
    ... 31 Reportlinker.com announces that a new market ... The Outlook for Pharmaceuticals In The ... http://www.reportlinker.com/p0285781/The-Outlook-for-Pharmaceuticals-In-The-Middle-East-And-North-Africa-To-2015.html ... social and demographic development is making the pharmaceutical ...
    Cached Medicine Technology:Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 2Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 3Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 4Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 5Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 6Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 7Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 9Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 10Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 11Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 12Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 13Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 14
    (Date:7/2/2015)... ... 2015 , ... Denver-based SlimGenics Weight Control Centers, the leader ... 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz compiles the exclusive ... award identifies outstanding woman-owned businesses that demonstrate excellence and success in the industry ...
    (Date:7/1/2015)... ... 2015 , ... With all final regulatory approvals in place ... N.Y., is now a member of national system Trinity Health, effective immediately. ... committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and CEO, ...
    (Date:7/1/2015)... ... 01, 2015 , ... For decades, researchers in the genetics field have theorized ... brain, never changing after development in the womb. Now, researchers from the Icahn School ... cells throughout life – a process which helps to switch genes on and off. ...
    (Date:7/1/2015)... ... 01, 2015 , ... Ormco Corporation, a leading manufacturer and ... Smile for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual ... S4L in its mission to provide free quality orthodontic care to individuals with ...
    (Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and ... Community Trust. The grant will allow CCF to improve quality of care and save ... was formed to respond to many changes in New York’s Medicaid system. Experts agree ...
    Breaking Medicine News(10 mins):Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
    ... 02, 2009 The antiepileptic drug vigabatrin (VGB) has been ... special form of epilepsy in infants, called infantile spasm. However, ... has been shown to cause a permanent narrowing of visual ... exposed at school age or later. A new study published ...
    ... U.S. Ambassador to the United Republic of Tanzania, joins Malaria ... No More Policy Center in Washington, DC, the non-profit organization ... fight against malaria in Africa to his new role at ... advocacy work to engage policymakers in the race to save ...
    ... given awayFORT WORTH, Texas, Feb. 2 ... USA announces the launch of the second season ... 26, 2009, Marinela USA consumers can collect one ... specially marked boxes of Barritas Fresa, Barritas Pina, ...
    ... and only multi-module training program devoted exclusively to whiplash ... Stutzman, local Doctor of Chiropractic practicing in Paoli, PA ... specifically to whiplash and brain injury traumatology. The ... prestigious Spine Research Institute of San Diego . ...
    ... Danaher Corporation (NYSE: DHR ) announced ... L. Comas will be presenting at the Barclays Capital ... 9, 2009 at 1:35 p.m. EST. The audio will ... of the webcast will be available for one week ...
    ... Digirad Corporation (Nasdaq: DRAD ), a ... equipment leasing services that improve patient care while driving ... the assets related to three northern California service hub ... Fe, Calif.-based MD Office Solutions calls for the sale ...
    Cached Medicine News:Health News:Controversial medication may decrease spasms for infants with epilepsy 2Health News:Recent U.S. Ambassador to Tanzania Mark Green Named Managing Director of Malaria No More Policy Center 2Health News:Marinela USA(R) Recharges ZumbAtomic for Second Season 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 3Health News:Digirad Corporation Sells Northern California Service Hubs 2
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
    The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
    Medicine Products: